Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 17/20 | 0.76 |
| ▸ | FLT3 | P36888 | 13/20 | 0.76 |
| ▸ | KDR | P35968 | 7/20 | 0.58 |
| ▸ | CSF1R | P07333 | 10/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 10/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171680 | 0.97 | PDGFRB (0.71) | PDGFRBFLT3KDRCSF1RKCNH2 | |
| SCHEMBL4168706 | 0.97 | PDGFRB (0.71) | PDGFRBFLT3KDRCSF1RKCNH2 | |
| SCHEMBL4175025 | 0.91 | PDGFRB (0.63) | PDGFRBFLT3KDRCSF1RKCNH2 | |
| SCHEMBL4178263 | 0.89 | PDGFRB (0.61) | PDGFRBFLT3KDRCSF1RKCNH2 | |
| SCHEMBL4175618 | 0.89 | PDGFRB (0.61) | PDGFRBFLT3KDRCSF1RKCNH2 | |
| SCHEMBL4161065 | 0.87 | PDGFRB (0.80) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL4172376 | 0.87 | PDGFRB (0.58) | PDGFRBFLT3KDRCSF1RKCNH2 | |
| SCHEMBL4168601 | 0.86 | PDGFRB (0.57) | PDGFRBFLT3KDRCSF1RKCNH2 | |
| SCHEMBL4174158 | 0.86 | PDGFRB (0.56) | PDGFRBFLT3KDRCSF1RKCNH2 | |
| SCHEMBL4172406 | 0.86 | PDGFRB (0.56) | PDGFRBFLT3KDRCSF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | PDGFRB 2332/4885FLT3 77/4885KDR 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.